Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Open access
Farago, Anna F., Yeap, Beow Y., Stanzione, Marcello, Hung, Yin P., Heist, Rebecca S., Marcoux, J. Paul, Zhong, Jun, Rangachari, Deepa, Barbie, David A., Phat, Sarah, Myers, David T., Morris, Robert, Kem, Marina, Dubash, Taronish D., Kennedy, Elizabeth A., Digumarthy, Subba R., Sequist, Lecia V., Hata, Aaron N., Maheswaran, Shyamala, Haber, Daniel A., Lawrence, Michael S., Shaw, Alice T., Mino-Kenudson, Mari, Dyson, Nicholas J., Drapkin, Benjamin J.·2019·Cancer Discovery

Abstract

Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP have modest single-agent activity. We performed a phase I/II trial of combination olaparib tablets and temozolomide (OT) in patients with previously treated SCLC. We established a recommended phase II dose of olaparib 200 mg orally twice daily with temozolomide 75 mg/m2 daily, both on days 1 to 7 of a 21-day cycle, and expanded to a total of 50 patients. The confirmed overall response rate was 41.7% (20/48 evaluable); median progression-free survival was 4.2 months [95% confidence interval (CI), 2.8–5.7]; and median overall survival was 8.5 months (95% CI, 5.1–11.3). Patient-derived xenografts (PDX) from trial patients recapitulated clinical OT responses, enabling a 32-PDX coclinical trial. This revealed a correlation between low basal expression of inflammatory-response genes and cross-resistance to both OT and standard first-line chemotherapy (etoposide/platinum). These results demonstrate a promising new therapeutic strategy in SCLC and uncover a molecular signature of those tumors most likely to respond. Significance: We demonstrate substantial clinical activity of combination olaparib/temozolomide in relapsed SCLC, revealing a promising new therapeutic strategy for this highly recalcitrant malignancy. Through an integrated coclinical trial in PDXs, we then identify a molecular signature predictive of response to OT, and describe the common molecular features of cross-resistant SCLC. See related commentary by Pacheco and Byers, p. 1340. This article is highlighted in the In This Issue feature, p. 1325

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0582

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 238

Metadata

Authors
Farago, A. F., Yeap, B. Y., Stanzione, M., Hung, Y. P., Heist, R. S., Marcoux, J. P., Zhong, J., Rangachari, D., Barbie, D. A., Phat, S., Myers, D. T., Morris, R., Kem, M., Dubash, T. D., Kennedy, E. A., Digumarthy, S. R., Sequist, L. V., Hata, A. N., Maheswaran, S., Haber, D. A., Lawrence, M. S., Shaw, A. T., Mino-Kenudson, M., Dyson, N. J., & Drapkin, B. J.
Venue
Cancer Discovery
Published
2019-10-01
Volume
9
Issue
10
Pages
1372-1387
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2969185256
Cited by
238
References
10
FWCI
10.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0582
The paper
Farago, A. F., Yeap, B. Y., Stanzione, M., Hung, Y. P., Heist, R. S., Marcoux, J. P., Zhong, J., Rangachari, D., Barbie, D. A., Phat, S., Myers, D. T., Morris, R., Kem, M., Dubash, T. D., Kennedy, E. A., Digumarthy, S. R., Sequist, L. V., Hata, A. N., Maheswaran, S., . . . Drapkin, B. J. (2019). Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0582

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.